Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
Open Access
- 1 June 2026
- journal article
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7) , 1026-1031
Abstract
Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating interleukin (IL)‐17 or IL‐23 inhibitors. This analysis reports safety outcomes in LTBI+ patients with moderate‐to‐severe PsO or active psoriatic arthritis (PsA) who received guselkumab for up to 5 years. Data were pooled from 11 phase 2/3 studies (7 PsO, 4 PsA). Guselkumab 100 mg was generally administered at Week 0, Week 4, then every 8 weeks (PsO studies) or every 4 or 8 weeks (PsA studies). Placebo‐randomized patients crossed over to guselkumab at Week 16 and Week 24 in PsO and PsA studies, respectively. Patients with active TB or a history of active TB were excluded. LTBI+ patients could participate if LTBI treatment was initiated before/with the first dose of study drug or if LTBI treatment was completed within 5 years before the first dose of study drug. Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). No new‐onset TB or LTBI reactivation occurred in any guselkumab‐treated patient. Through Year 1, liver transaminase elevations were more common in LTBI+ vs. LTBI− patients; ≤ 2% of LTBI+ patients had CTCAE Grade 3 elevations vs. 0.5% of LTBI− patients (no LTBI+ patients had Grade 4 elevations). From Year 1–5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI− patients. The absence of observed TB risk in guselkumab‐treated patients suggests IL‐23 inhibitors may be better treatment options than TNFi in high‐risk patients, including those in TB‐endemic regions.Keywords
Funding Information
- Johnson and Johnson
This publication has 15 references indexed in Scilit:
- Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsJournal of the American Academy of Dermatology, 2025
- Safety of guselkumab and ustekinumab treatment in patients with moderate-to-severe plaque psoriasis combined with latent tuberculosis or inactive hepatitis B virus infection: A retrospective multicenter observational studyJournal of the American Academy of Dermatology, 2025
- Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive reviewAutoimmunity Reviews, 2025
- Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective studyJournal of Dermatological Treatment, 2023
- Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisJournal of the American Academy of Dermatology, 2022
- Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm changeJournal of the European Academy of Dermatology and Venereology, 2020
- Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trialsJournal of the European Academy of Dermatology and Venereology, 2020
- Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trialBritish Journal of Dermatology, 2017
- Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective studyJournal of the European Academy of Dermatology and Venereology, 2016
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisNew England Journal of Medicine, 2015